Application of H1.2 as target spot in preparation of drugs for enhancing antiviral immunity and antiviral infection

By targeting the mechanism of H1.2 to regulate cGAS and using Sp1 small molecule inhibitor Placamycin, the problem of insufficient broad spectrum of existing antiviral drugs has been solved, the antiviral immunity ability is enhanced, and new antiviral treatment ideas and potential are provided. Drug application.

CN118924901APending Publication Date: 2024-11-12SHANGHAI PUBLIC HEALTH CLINICAL CENT
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410997790.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing antiviral drugs are insufficient in broad spectrum, making it difficult to effectively cope with the high mutation and immune escape of the virus, making it difficult to effectively improve the host's antiviral immunity.

Method used

By targeting the mechanism of H1.2 to regulate cGAS, the Sp1 small molecule inhibitor Plicamycin is used to inhibit the expression of H1.2, enhance the antiviral immunity, and provide a new antiviral treatment idea.

Benefits of technology

For the first time, H1.2 is the negative regulatory element in the nuclear nucleus of cGAS, and it was discovered that the role of Sp1-H1.2-cGAS axis in innate immunity. Plicamycin inhibits H1.2 expression and enhances antiviral immunity and provides potential antiviral drug applications. , especially suitable for patients with clinical tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004960736320000011
    Figure HDA0004960736320000011
  • Figure HDA0004960736320000012
    Figure HDA0004960736320000012
  • Figure HDA0004960736320000013
    Figure HDA0004960736320000013
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, and discloses application of H1.2 as a target spot in preparation of drugs for enhancing antiviral immunity and antiviral infection. The invention proposes that H1.2 is an intranuclear negative regulation element of cGAS for the first time, clarifies a mechanism of regulating cGAS by H1.2, provides a new theoretical support for deep research and development of cGAS, and also provides a new research target H1.2 for development of antiviral drugs. The invention further discloses application of the substance for inhibiting expression of H1.2 in the infection period in preparation of drugs for enhancing antiviral immunity and antiviral infection, and it is found for the first time that during infection, an organism regulates expression of H1.2 through the Sp1-H1.2 way, and then the activity of downstream cGAS is affected. According to the present invention, the small molecule inhibitor Plicamycin of Sp1 can inhibit the expression of H1.2 during the infection period by inhibiting Sp1 so as to enhance the anti-virus immunity of the body;
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine, and more specifically, it relates to the use of H1.2 as a target in the preparation of drugs for enhancing antiviral immunity and antiviral infection. Background Art

[0002] Viruses have high environmental adaptability and high mutation rate, and the infectious diseases they cause pose a huge threat to human health and global property security. Viruses can cause a variety of epidemics, and their high mutation rate and multiple immune escape mechanisms enable them to lurk and hide in the human body and escape immune surveillance. Most existing antiviral drugs focus on specific viral protein subunit structures and lack broad spectrum, so we focus on the host itself and fight viral infection by improving the host's antiviral immunity.

[0003] cGAS is an important DNA receptor in cells. It can recognize and bind to free viruses and bacterial dsDNA in the cytoplasm. After binding, cGAS is activated and dimerizes under the catalysis of ATP and GTP to form 2',3' cyclic GMP-AMP. It binds to and activates the interferon-activating protein STING in the endoplasmic reticulum. The activated STING dimerizes, recruits and activates molecules such as TBK1, IRF3, NF-кB, and ultimately initiates the transcription of downstream cytokines such as IFN and IL6. The interferon response based on the cGAS-STING pathway is one of the important pathways for the body to resist viral infection.

[0004] H1.2 is a subtype of the histone H1 family and the most widely-existing subtype of the H1 family. It is a housekeeping gene with strong species conservation. It is involved in DNA damage repair and tumor immunity. Our previous data showed that H1.2 and cGAS have a binding effect, and overexpression of H1.2 can significantly inhibit the interferon response of cells. Therefore, H1.2 may be an upstream regulatory element of cGAS in cells and has good development potential in the treatment of antiviral immunity. Summary of the invention

[0005] In order to study the relevant mechanism of H1.2 regulating intracellular cGAS and provide a new idea for the treatment of antiviral immunity, the present application provides an application of H1.2 as a target in the preparation of drugs that enhance antiviral immunity and antiviral infection.

[0006] In a first aspect, the present application discloses the use of H1.2 as a target in the preparation of drugs for enhancing antiviral immunity and antiviral infection.

[0007] Furthermore, the H1.2 enhances antiviral immunity and antiviral infection by regulating cGAS.

[0008] In a second aspect, the present application discloses the use of a substance that inhibits the expression of H1.2 during infection in the preparation of a drug for enhancing antiviral immunity and antiviral infection.

[0009] Furthermore, the substance that inhibits the expression of H1.2 during infection is a small molecule inhibitor of Sp1.

[0010] Furthermore, the substance that inhibits the expression of H1.2 during infection is Plicamycin.

[0011] In summary, this application has the following beneficial effects:

[0012] 1. This invention proposes for the first time that H1.2 is a negative regulatory element in the nucleus of cGAS, clarifies the mechanism by which H1.2 regulates cGAS, provides new theoretical support for the in-depth research and development of cGAS, and also provides a new research target H1.2 for the development of antiviral drugs.

[0013] 2. The present invention is the first to discover the role of the Sp1-H1.2-cGAS axis in innate immunity and the body's spontaneous regulation mode. The present invention proposes a theoretical support that under viral infection conditions, the body regulates H1.2 expression through the Sp1-H1.2 pathway, thereby affecting the activity of downstream cGAS.

[0014] 3. The present invention also discovered for the first time that the small molecule inhibitor of Sp1, Plicamycin, can inhibit the expression of H1.2 during infection by inhibiting Sp1, thereby enhancing the body's antiviral immunity. Therefore, Plicamycin can be used as a potential antiviral drug in clinical treatment, especially in the case of co-infection in clinical tumor patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 :cGAS interacts with H1.2;

[0016] (A: Immunoprecipitation results of exogenous target proteins expressed in HEK293T cells; B: GST-Pull down results after purification of two proteins in the prokaryotic system);

[0017] Figure 2 : Loss of H1.2 can enhance cellular interferon levels;

[0018] (A: Primary peritoneal macrophages from wild-type mice and H1.2 knockout mice were extracted and infected with HSV-1, and the mRNA levels of intracellular cytokines such as IFN and isg15 were detected; B: Primary peritoneal macrophages from wild-type mice and H1.2 knockout mice were extracted, infected with HSV-1 for a specific period of time, and the levels of intracellular phosphorylation of proteins such as STING, TBK1, IRF3, and P65 were detected);

[0019] Figure 3 :H1.2 deficiency can enhance the body's anti-infection immune response;

[0020] (A: HE-stained sections of mouse lung tissue, confirming that H1.2 deficiency can reduce the damage to the lungs caused by viral infection; B: H1.2 deficiency can reduce the viral load in the lungs; C: H1.2 deficiency can enhance the expression of IFN in the peripheral blood of mice);

[0021] Figure 4 :The Sp1-H1.2 axis is involved in immune regulation during infection;

[0022] (A: After HSV-1 infection, cells spontaneously downregulate the transcription level of H1.2; B: Sp1, as an upstream positive transcription factor of H1.2, can significantly promote the expression of H1.2 transcription level; C: Sp1 participates in antiviral immunity, and Sp1 can significantly inhibit the activation level of cellular interferon pathway proteins such as STING);

[0023] Figure 5 :Plicamycin is used as an anti-infective drug in antiviral immunity;

[0024] (A: Activation of the IFN signaling pathway when primary mouse peritoneal macrophages were infected with HSV-1 under Plicamycin treatment; B: The effect of Plicamycin treatment on the transcription level of IFN-β under infection, and this effect specifically acts on H1.2; C: Plicamycin treatment can inhibit the replication ability of intracellular HSV-1; D: Giving mice Plicamycin treatment after infection can reduce the damage of the virus to tissues). DETAILED DESCRIPTION

[0025] The technical scheme and effects of the present application are further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the invention, rather than to limit the invention.

[0026] Plicamycin and Flag-beads were purchased from MedChemExpress; Super Signal West chemiluminescent substrates were purchased from Vazyme; primary antibody H1.2 was purchased from Proteintech; primary antibodies STING, TBK1, P65.IRF3 and their phosphorylation antibodies were purchased from CellSignaling Technology; primary antibodies HA, FLAG, GAPDH were purchased from Abclonal; primary antibody GFAP was purchased from Biolegend.

[0027] The statistical analysis involved in the present invention was performed using GraphPad Prism statistical software, the mean values ​​of two groups were compared using t-test, and the mean values ​​of multiple groups were compared using one-way analysis of variance, and P<0.05 was considered to be statistically significant.

[0028] Example 1: cGAS has a direct effect on H1.2

[0029] (1) cGAS binds to H1.2 in cells ( Figure 1 -A).

[0030] Sample preparation:

[0031] 1) In a 6 cm dish HEK293T cells that was 70%-80% full, cationic liposomes were used to transfect the designated plasmids, the medium was changed after 4-6 hours, and the samples were collected after 48 hours.

[0032] 2) Wash the cells twice with PBS, add 500 μL IP lysis buffer, and lyse at 4°C for 30 minutes.

[0033] 3) Centrifuge at 13200r, 4℃ for 15min, add Flag-beads to 400μL supernatant for IP, rotate at 4℃ overnight; 75μL supernatant as lysate, add 25μL 4x loading buffer, incubate at 100℃ for 10min, and set aside.

[0034] 5) Wash beads: Remove the EP tube, centrifuge at 1000r for 5min, place the IP tube on a magnetic rack, aspirate the liquid, retain the beads, add 1mL 1xPBST, rotate for 5min, place on a magnetic rack, aspirate the liquid, repeat 3 times, aspirate the supernatant for the last time, add 100μL 1xloading (IP lysate diluted 4x), and heat at 100℃ for 10min.

[0035] Electrophoresis:

[0036] 1) Prepare 10% separation gel (prepare according to the instructions) and aspirate the residual gel in the well before loading the sample.

[0037] 2) Load 3 μL marker protein and 10 μg sample, calculate the corresponding volume according to the protein concentration, and use loading buffer to make up the maximum volume;

[0038] 3) Electrophoresis: Concentrating gel 80 mV, 30 min; Separating gel 110-120 mV, 80 min.

[0039] 4) Transfer: Cut a PVDF membrane of 4 cm*8 cm, activate it in methanol in advance, install the electrotransfer clamp in the order of black clamp-sponge-filter paper-glue-PVDF membrane-filter paper-sponge-white clamp, and set the transfer time at 100 V and 1 KD / min.

[0040] 5) Blocking: Block with 5% skim milk for 1 hour, and wash three times with TBST (conventional membrane washing solution), each time for 5 minutes.

[0041] 6) Incubation with primary antibody: Incubate with primary antibody at 4°C overnight.

[0042] 7) Wash three times with TBST, 5 min each time, incubate with secondary antibody (secondary antibody is an antibody that binds to the primary antibody and carries an enzyme that can react with the substrate in the luminescent solution) for 60 min, and wash three times with TBST, 5 min each time.

[0043] 8) Development.

[0044] (2) cGAS binds to H1.2 outside the cell ( Figure 1 -B).

[0045] 1) The His-tagged and GST-tagged proteins were cultured in 100 mL LB until OD600 = 0.4-0.6, 1000xIPTG (final concentration 1 mM) was added, and induced at 30°C 180r for 4-6h, or overnight;

[0046] 2) Collect the cells at 8000r / 3min, resuspend the cells with lysis buffer (100mL of cells plus 5mL of lysis buffer and mix well) and ultrasonically disrupt them (ultrasonic disruption needs to be performed on an ice-water mixture); ultrasonic disruption: work for 3s, pause for 3s, and the total duration is 30min;

[0047] 3) Centrifuge at 4°C, 13200r, 15min, take the supernatant, filter with 0.22 / 0.45um filter, and add to new 1.5mL EP;

[0048] 4) His-tagged protein: Take the Ni column, release 20% ethanol, and rinse in the order of ddH2O-20mM imidazole rinse solution-30mM imidazole rinse solution-filtered lysate-50mM imidazole rinse solution, add 300mM imidazole eluent to elute the His-tagged protein, and recover the 300mM eluent, a total of 5mL, add only 1mL imidazole each time, discard the first 1mL and the last 1mL, and add 150mM imidazole rinse solution-ddH2O-20% ethanol for storage after the elution is completed;

[0049] 5) GST-tagged protein: Prepare 120μL lysate, take 1mL protein solution, add 20μL washed GST-beads, incubate at 4℃ for 3h, remove the EP tube and place it on the magnetic rack, aspirate the liquid, add 1mL PBST and rotate and mix for 5min, aspirate the liquid, repeat 3 times. Add 1mL His-tagged protein solution, rotate at 4℃ overnight, wash 3 times with PBST the next day, and prepare 100μL sample.

[0050] 6) Electrophoresis.

[0051] 7) Development.

[0052] Example 2: Deletion of H1.2 can enhance cellular interferon levels

[0053] (1) H1.2 deficiency can enhance the mRNA levels of IFN and ISG15 in infected cells ( Figure 2 -A).

[0054] 1) Cell collection: ① Three days before the experiment, 1 mL of 3% thioglycolate broth was injected into the mouse peritoneum to obtain more macrophages. Metal instruments such as ophthalmic scissors and ophthalmic forceps were sterilized by high pressure, centrifuge tubes were irradiated and sterilized, mice were fasted for 8 hours, and the clean bench was ultraviolet disinfected for 30 minutes before the experiment. ② The mice were killed by dislocation of the neck, and the whole mouse was immersed in 70% alcohol for 3 to 5 seconds, and then supine on a stainless steel square plate, and physiological saline or cell culture medium was injected into the peritoneum. The mouse abdomen was gently rubbed several times, and it was left to stand for 3-5 minutes to allow the fluid to flow fully in the abdominal cavity. ③ The peritoneum was exposed by dissection, and the lower abdominal skin was lifted with forceps to separate it from the peritoneum. A small incision was made in the skin at the extraction point of the forceps, and then the entire abdominal skin was cut open, and the skin on both sides was pinched and slowly torn to both sides to expose the peritoneum. To extract peritoneal fluid, pinch the skin on one side of the mouse with your hand to squeeze the internal organs to form a cavity in the abdominal cavity, insert the syringe needle into the gap to extract peritoneal fluid, and then inject the peritoneal fluid into the centrifuge tube. ④ Centrifuge the collected peritoneal lavage fluid at 1000r / min for 10min, discard the supernatant, add cell culture medium to resuspend and count the cells. After adjusting the cell concentration, inoculate it into a 6-well cell plate and incubate it in a 37℃ incubator for 4-6h. After the macrophages are fully attached to the wall, discard the supernatant, replace with new cell culture medium, and return it to the incubator for continued cultivation.

[0055] 2) Infection: Before infection, pure culture starved cells were replaced and HSV-1 was added at a dose of MOI = 10 for a specific time.

[0056] 3) Sample collection: Add 1 mL of TRIZOL (all subsequent EP tubes, washing heads, etc. are RNAase free), pipette to mix well, and transfer to a new EP tube.

[0057] 4) Add 200 μL of chloroform, cover the tube, shake vigorously for 15 seconds, and leave at room temperature for 5 minutes. Centrifuge at 12000r for 15 minutes. The sample will separate into three layers. Take 400 μL of the upper aqueous phase, add 400 μL of isopropanol, leave at room temperature for 10 minutes, centrifuge at 10000r for 10 minutes, and discard the supernatant.

[0058] 5) Wash the RNA precipitate with 75% ethanol, centrifuge at 10,000 r / min for 5 minutes, discard the supernatant, and repeat 3 times.

[0059] 6) Place the dried RNA precipitate at room temperature, add an appropriate amount of RNase-free water, pipette several times to dissolve the RNA, and test the RNA concentration and purity.

[0060] 7) Reversal: The reagent used is Vazyme's HiScript IV RT SuperMix for qPCR (R423-01) kit, and the kit is followed to reverse into cDNA.

[0061] 8) qPCR: Load the sample according to the system of 0.2 μL upstream and downstream primers + 1 μL cDNA + 3.6 μL ddH2O + 5 μL 2Xsybr, use Vazyme's ChamQ Blue Universal SYBR qPCR Master Mix as reagent, use Roche 480 as instrument, and export data.

[0062] (2) H1.2 deficiency can enhance the activation of the type I interferon pathway in infected cells ( Figure 2 -B).

[0063] 1) Cell collection: ① Three days before the experiment, 1 mL of 3% thioglycolate broth was injected into the mouse peritoneum to obtain more macrophages. Metal instruments such as ophthalmic scissors and ophthalmic forceps were sterilized by high pressure, centrifuge tubes were irradiated and sterilized, mice were fasted for 8 hours, and the clean bench was ultraviolet disinfected for 30 minutes before the experiment. ② The mice were killed by dislocation of the neck, and the whole mouse was immersed in 70% alcohol for 3 to 5 seconds, and then supine on a stainless steel square plate, and physiological saline or cell culture medium was injected into the peritoneum. The mouse abdomen was gently rubbed several times, and it was left to stand for 3-5 minutes to allow the fluid to flow fully in the abdominal cavity. ③ The peritoneum was exposed by dissection, and the lower abdominal skin was lifted with forceps to separate it from the peritoneum. A small incision was made in the skin at the extraction point of the forceps, and then the entire abdominal skin was cut open, and the skin on both sides was pinched and slowly torn to both sides to expose the peritoneum. To extract peritoneal fluid, pinch the skin on one side of the mouse with your hand to squeeze the internal organs to form a cavity in the abdominal cavity, insert the syringe needle into the gap to extract peritoneal fluid, and then inject the peritoneal fluid into the centrifuge tube. ④ Centrifuge the collected peritoneal lavage fluid at 1000r / min for 10min, discard the supernatant, add cell culture medium to resuspend and count the cells. After adjusting the cell concentration, inoculate it into a 6-well cell plate and incubate it in a 37℃ incubator for 4-6h. After the macrophages are fully attached to the wall, discard the supernatant, replace with new cell culture medium, and return it to the incubator for continued cultivation.

[0064] 2) Infection: Before infection, pure culture starved cells were replaced and HSV-1 was added at a dose of MOI = 10 for a specific time.

[0065] 3) Sample collection: add 200 μL cell lysis buffer (Biyuntian, P0013, add PMSF, cocktail, NaF and sodium pervanadate to inhibit phosphorylated protein degradation), lyse at 4°C for 40 minutes, transfer to a new EP tube by pipetting, centrifuge at 13200r, 4°C for 15 minutes, take 150 μL supernatant, add loading, and cook the sample at 100°C for 10 minutes.

[0066] 4) Electrophoresis: Prepare 10% separation gel (prepare according to the instructions), and aspirate the residual gel in the well before loading the sample; load 3 μL marker protein and 10 μg sample, calculate the corresponding volume according to the protein concentration, and use loading buffer to make up the maximum volume; concentrate gel 80mV, 30min; separate gel 110-120mV, 80min.

[0067] 5) Transfer: Cut a PVDF membrane of 4 cm*8 cm, activate it in methanol in advance, install the electrotransfer clamp in the order of black clamp-sponge-filter paper-glue-PVDF membrane-filter paper-sponge-white clamp, and set the transfer time at 100 V and 1 KD / min.

[0068] 6) Blocking: Block with 5% skim milk for 1 hour, wash three times with TBST (conventional membrane washing solution), 5 minutes each time.

[0069] 7) Incubation with primary antibody: Incubate with primary antibody at 4°C overnight.

[0070] 8) Wash three times with TBST, 5 min each time, incubate with secondary antibody (secondary antibody is an antibody that binds to the primary antibody and carries an enzyme that can react with the substrate in the luminescent solution) for 60 min, and wash three times with TBST, 5 min each time.

[0071] 9) Development.

[0072] Example 3: H1.2 deficiency can enhance the body's anti-infection immune response

[0073] (1) The absence of H1.2 can reduce the damage caused by viral infection to the lungs ( Figure 3 -A).

[0074] 1) Materials: 6-8 week old wild-type male mice and H1.2 knockout mice were collected according to PFU10 8 / mouse were injected intraperitoneally with HSV-1, and the animals were killed by cervical dislocation 48 hours later. The right lung tissues were obtained for sectioning and fixed with tissue fixative.

[0075] 2) Wash off the fixative with PBS, add hematoxylin for staining, and control the staining time according to the tissue condition and dye condition (usually about 5 minutes. As the hematoxylin is left for a longer time, the hematoxylin staining effect will be enhanced, and the time should be shortened appropriately).

[0076] 3) Wash with water until the tissue turns blue-purple, add 1% hydrochloric acid ethanol for differentiation for 2 seconds, and wait until the tissue turns red.

[0077] 4) Wash off the hydrochloric acid ethanol with water until the tissue turns blue, then stain with eosin. Control the staining time according to the tissue and dye conditions (usually about 2s to 8s), wash off the dye with water, cover the tissue with glycerol, and confirm the staining under a microscope. If the staining is intact, the slide should be sealed.

[0078] 5) Observe the sections under an optical microscope.

[0079] (2) H1.2 deficiency can reduce the viral titer in infected tissues ( Figure 3 -B).

[0080] 1) Materials: 6-8 week old wild-type male mice and H1.2 knockout mice were collected according to PFU10 8 The mice were intraperitoneally injected with HSV-1 at a dose of 1:1.5 / mouse. The mice were killed by cervical dislocation 48 hours later. An appropriate amount of right lung tissue was taken, added with 1 mL of DMEM, ground, centrifuged at 10,000 r / min for 5 minutes, and the supernatant was aspirated.

[0081] 2) Vero cells were plated in advance on a 96-well plate, and 0.22 μL of the virus solution obtained in 1) was filtered through a filter and diluted by a multiple of 10.

[0082] 3) Aspirate the culture medium in the culture plate and add the diluted virus solution in 2). Make 8 duplicate wells for each gradient. Leave one column of wells and add new culture medium as a control.

[0083] 4) After 5 days of culture in a cell culture incubator, the number of wells with gradient lesions was observed under a microscope, and the virus titer was calculated according to the TCID50 method.

[0084] (3) H1.2 deficiency can enhance the expression of IFN in peripheral blood of mice ( Figure 3 -C).

[0085] 1) Wild-type mice or knockout mice (6-8 weeks, male) were injected with HSV-1 and blood was collected 48 hours later.

[0086] 2) Sampling: Anesthetize mice, and the anesthesia method can be general anesthesia with anesthetics; fix the mice, before blood collection, use the thumb and index finger of the left hand to grasp the skin between the two ears of the mouse and fix it, and gently press the sides of the neck to make the orbital venous sinus congested and the eyeball fully protruded; for blood collection, hold the blood collection tube (or capillary) in the right hand, insert its tip between the inner corner of the eye and the eyeball, and gently pierce it toward the larynx. When resistance is felt, stop piercing, rotate the blood collection tube to cut the venous sinus, and the blood will flow into the blood collection tube; stop bleeding and handle, after blood collection, pull out the blood collection tube, relax the left hand, and use dry cotton balls to press and stop bleeding; 0.2-0.3mL of blood can be collected from mice weighing 20-30g at a time.

[0087] 3) The blood sample was allowed to stand at room temperature for 30 minutes, centrifuged at 4000r for 10 minutes, and the upper layer of serum was transferred to a new EP tube.

[0088] 4) Elisa assay was performed using the mouse IFN-β kit (mL063095) from ELISA, and the use and data processing were performed according to the instructions.

[0089] Example 4: Sp1-H1.2 axis is involved in immune regulation during infection

[0090] (1) During infection, cells spontaneously downregulate the expression of H1.2 transcription levels ( Figure 4 -A).

[0091] 1) Cell collection: ① Three days before the experiment, 1 mL of 3% thioglycolate broth was injected into the mouse peritoneum to obtain more macrophages. Metal instruments such as ophthalmic scissors and ophthalmic forceps were sterilized by high pressure, centrifuge tubes were irradiated and sterilized, mice were fasted for 8 hours, and the clean bench was ultraviolet disinfected for 30 minutes before the experiment. ② The mice were killed by dislocation of the neck, and the whole mouse was immersed in 70% alcohol for 3 to 5 seconds, and then supine on a stainless steel square plate, and physiological saline or cell culture medium was injected into the peritoneum. The mouse abdomen was gently rubbed several times, and it was left to stand for 3-5 minutes to allow the fluid to flow fully in the abdominal cavity. ③ The peritoneum was exposed by dissection, and the lower abdominal skin was lifted with forceps to separate it from the peritoneum. A small incision was made in the skin at the extraction point of the forceps, and then the entire abdominal skin was cut open, and the skin on both sides was pinched and slowly torn to both sides to expose the peritoneum. To extract peritoneal fluid, pinch the skin on one side of the mouse with your hand to squeeze the internal organs to form a cavity in the abdominal cavity, insert the syringe needle into the gap to extract peritoneal fluid, and then inject the peritoneal fluid into the centrifuge tube. ④ Centrifuge the collected peritoneal lavage fluid at 1000r / min for 10min, discard the supernatant, add cell culture medium to resuspend and count the cells. After adjusting the cell concentration, inoculate it into a 6-well cell plate and incubate it in a 37℃ incubator for 4-6h. After the macrophages are fully attached to the wall, discard the supernatant, replace with new cell culture medium, and return it to the incubator for continued cultivation.

[0092] 2) Infection: Before infection, pure culture starved cells were replaced and HSV-1 was added at a dose of MOI = 10 for a specific time.

[0093] 3) Collect samples: Add 1 mL TRIZOL (all subsequent EP tubes, washing heads, etc. are RNAase free), pipette to mix well, and transfer to a new EP tube.

[0094] 4) Add 200 μL of chloroform, cover the tube, shake vigorously for 15 seconds, and leave at room temperature for 5 minutes; centrifuge at 12000r for 15 minutes, the sample will separate into three layers, take 400 μL of the upper aqueous phase, add 400 μL of isopropanol, leave at room temperature for 10 minutes, centrifuge at 10000r for 10 minutes, and discard the supernatant.

[0095] 5) Wash the RNA precipitate with 75% ethanol, centrifuge at 10,000 r / min for 5 minutes, discard the supernatant, and repeat 3 times.

[0096] 6) Place the dried RNA precipitate at room temperature, add an appropriate amount of RNase-free water, pipette several times to dissolve the RNA, and test the RNA concentration and purity.

[0097] 7) Reversal: The reagent used is Vazyme's HiScript IV RT SuperMix for qPCR (R423-01) kit, and the kit is followed to reverse into cDNA.

[0098] 8) qPCR: Load the sample according to the system of 0.2 μL upstream and downstream primers + 1 μL cDNA + 3.6 μL ddH2O + 5 μL 2Xsybr, use Vazyme's ChamQ Blue Universal SYBR qPCR Master Mix as reagent, use Roche 480 as instrument, and export data.

[0099] (2) Sp1 affects the transcription level of H1.2 during infection ( Figure 4 -B).

[0100] 1) Transfection: L929 cells were transfected with exogenous Sp1 or control using cationic liposomes, the medium was changed every 4-6 hours, the cells were starved after 36 hours, and then infected.

[0101] 2) Collect the sample: add 1 mL TRIZOL (all subsequent EP tubes, washing heads, etc. are RNAase free), pipette to mix well, and transfer to a new EP tube.

[0102] 3) Reversal: The reagent used was HiScript IV RT SuperMix for qPCR (R423-01) kit from Vazyme, and the DNA was reversed into cDNA according to the instructions of the kit.

[0103] 4) qPCR: Load the sample according to the system of 0.2 μL upstream and downstream primers + 1 μL cDNA + 3.6 μL ddH2O + 5 μL 2Xsybr, use Vazyme's ChamQ Blue Universal SYBR qPCR Master Mix as reagent, use Roche 480 as instrument, and export data.

[0104] (3) Sp1 is involved in antiviral immunity of cells under virus infection ( Figure 4 -C).

[0105] 1) Transfection: L929 cells were transfected with exogenous Sp1 or control using cationic liposomes, and the medium was changed every 4-6 hours. After 36 hours, the cells were starved and infected.

[0106] 2) Sample collection: Add 200 μL cell lysis buffer (Biyuntian, P0013, add PMSF, cocktail, NaF and sodium pervanadate to inhibit phosphorylated protein degradation), lyse at 4 degrees for 40 minutes, transfer to a new EP tube by pipetting, centrifuge at 13200r, 4 degrees for 15 minutes. Take 150 μL supernatant, add loading, and boil the sample at 100°C for 10 minutes.

[0107] 3) Electrophoresis.

[0108] 4) Development.

[0109] Example 5: Plicamycin as an anti-infective drug for antiviral immunity

[0110] (1) Activation of IFN signaling pathway during HSV-1 infection under Plicamycin treatment ( Figure 5 -A).

[0111] 1) Cell collection: ① Three days before the experiment, 1 mL of 3% thioglycolate broth was injected into the mouse peritoneum to obtain more macrophages. Metal instruments such as ophthalmic scissors and ophthalmic forceps were sterilized by high pressure, centrifuge tubes were irradiated and sterilized, mice were fasted for 8 hours, and the clean bench was ultraviolet disinfected for 30 minutes before the experiment. ② The mice were killed by dislocation of the neck, and the whole mouse was immersed in 70% alcohol for 3 to 5 seconds, and then supine on a stainless steel square plate, and physiological saline or cell culture medium was injected into the peritoneum. The mouse abdomen was gently rubbed several times, and it was left to stand for 3-5 minutes to allow the fluid to flow fully in the abdominal cavity. ③ The peritoneum was exposed by dissection, and the lower abdominal skin was lifted with forceps to separate it from the peritoneum. A small incision was made in the skin at the extraction point of the forceps, and then the entire abdominal skin was cut open, and the skin on both sides was pinched and slowly torn to both sides to expose the peritoneum. To extract peritoneal fluid, pinch the skin on one side of the mouse with your hand to squeeze the internal organs to form a cavity in the abdominal cavity, insert the syringe needle into the gap to extract peritoneal fluid, and then inject the peritoneal fluid into the centrifuge tube. ④ Centrifuge the collected peritoneal lavage fluid at 1000r / min for 10min, discard the supernatant, add cell culture medium to resuspend and count the cells. After adjusting the cell concentration, inoculate it into a 6-well cell plate and incubate it in a 37℃ incubator for 4-6h. After the macrophages are fully attached to the wall, discard the supernatant, replace with new cell culture medium, and return it to the incubator for continued cultivation.

[0112] 2) Cells were treated with DMSO or Plicamycin (100 nM), and HSV-1 was added for infection 12 hours later.

[0113] 3) Sample collection: Add 200 μL cell lysis buffer (Biyuntian, P0013, add PMSF, cocktail, NaF and sodium pervanadate to inhibit phosphorylated protein degradation), lyse at 4°C for 40 minutes, transfer to a new eppendorf tube by pipetting, centrifuge at 13200r, 4°C for 15 minutes. Take 150 μL supernatant, add loading, and boil the sample at 100°C for 10 minutes.

[0114] 4) Electrophoresis.

[0115] 5) Development.

[0116] (2) Plicamycin promotes IFN-β transcription level in infection state by affecting H1.2 Figure 5 -B, C).

[0117] 1) Cell collection: ① Three days before the experiment, 1 mL of 3% thioglycolate broth was injected into the mouse peritoneum to obtain more macrophages. Metal instruments such as ophthalmic scissors and ophthalmic forceps were sterilized by high pressure, centrifuge tubes were irradiated and sterilized, mice were fasted for 8 hours, and the clean bench was ultraviolet disinfected for 30 minutes before the experiment. ② The mice were killed by dislocation of the neck, and the whole mouse was immersed in 70% alcohol for 3 to 5 seconds, and then supine on a stainless steel square plate, and physiological saline or cell culture medium was injected into the peritoneum. The mouse abdomen was gently rubbed several times, and it was left to stand for 3-5 minutes to allow the fluid to flow fully in the abdominal cavity. ③ The peritoneum was exposed by dissection, and the lower abdominal skin was lifted with forceps to separate it from the peritoneum. A small incision was made in the skin at the extraction point of the forceps, and then the entire abdominal skin was cut open, and the skin on both sides was pinched and slowly torn to both sides to expose the peritoneum. To extract peritoneal fluid, pinch the skin on one side of the mouse with your hand to squeeze the internal organs to form a cavity in the abdominal cavity, insert the syringe needle into the gap to extract peritoneal fluid, and then inject the peritoneal fluid into the centrifuge tube. ④ Centrifuge the collected peritoneal lavage fluid at 1000r / min for 10min, discard the supernatant, add cell culture medium to resuspend and count the cells. After adjusting the cell concentration, inoculate it into a 6-well cell plate and incubate it in a 37℃ incubator for 4-6h. After the macrophages are fully attached to the wall, discard the supernatant, replace with new cell culture medium, and return it to the incubator for continued cultivation.

[0118] 2) Cells were treated with DMSO or Plicamycin (100 nM), and HSV-1 was added for infection 12 hours later.

[0119] 3) Sample collection: Add 200 μL cell lysis buffer (Biyuntian, P0013, add PMSF, cocktail, NaF and sodium pervanadate to inhibit phosphorylated protein degradation), lyse at 4°C for 40 minutes, transfer to a new eppendorf tube by pipetting, centrifuge at 13200r, 4°C for 15 minutes. Take 150 μL supernatant, add loading, and boil the sample at 100°C for 10 minutes.

[0120] 4) Reversal: The reagent used was HiScript IV RT SuperMix for qPCR (R423-01) kit from Vazyme, and the DNA was reversed into cDNA according to the instructions of the kit.

[0121] 5) qPCR: Load the sample according to the system of 0.2 μL upstream and downstream primers + 1 μL cDNA + 3.6 μL ddH2O + 5 μL 2Xsybr, use Vazyme's ChamQ Blue Universal SYBR qPCR Master Mix as reagent, use Roche 480 as instrument, and export data.

[0122] (3) Giving mice Plicamycin treatment after infection can reduce viral damage to tissues ( Figure 5 -D).

[0123] 1) Materials: 6-week-old wild-type male mice were given HSV-1 (PFU10 8 After 24 hours of infection with PBS or 0.2 mg / kg plicamycin or control treatment (diluted with saline and injected intraperitoneally), the mice were killed by cervical dislocation and the right lung tissue was obtained, sliced ​​and fixed.

[0124] 2) Wash off the fixative with PBS, add hematoxylin for staining, and control the staining time according to the tissue condition and dye condition (usually about 5 minutes. As the hematoxylin is left for a longer time, the hematoxylin staining effect will be enhanced, and the time should be shortened appropriately).

[0125] 3) Wash with water until the tissue turns blue-purple, add 1% hydrochloric acid ethanol for 2 seconds, and wait until the tissue turns red.

[0126] 4) Wash off the hydrochloric acid ethanol with water until the tissue turns blue, then stain with eosin. Control the staining time according to the tissue and dye conditions (usually about 2s to 8s). Wash off the dye with water, cover the tissue with glycerol, and confirm the staining under a microscope. If the staining is intact, the slide should be sealed.

[0127] 5) Observe the sections under an optical microscope.

[0128] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.

Claims

1. Application of H1.2 as a target in the preparation of drugs for enhancing antiviral immunity and antiviral infection.

2. The use according to claim 1, characterized in that: The H1.2 enhances antiviral immunity and antiviral infection by regulating cGAS.

3. Use of substances that inhibit the expression of H1.2 during infection in the preparation of drugs for enhancing antiviral immunity and antiviral infection.

4. The use according to claim 3, characterized in that: The substance that inhibits the expression of H1.2 during infection is a small molecule inhibitor of Sp1.

5. The use according to claim 4, characterized in that: The substance that inhibits the expression of H1.2 during infection is Plicamycin.

Citation Information

Cited By

  • Use of h1.2 as target in preparation of drug for enhancing antiviral immunity and antiviral infection

    WO2026021615A1